Home › Research › Inflammation and the immune system
Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies
Corraliza-Gomez M, Vargas-Soria M, Garcia-Alloza M.. Molecular neurodegeneration, 2025-10-27
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The potential neuroprotective effects of antidiabetic treatments have been largely assessed in Alzheimer's disease (AD) and AD-like dementia models, with or without metabolic disorders. In this Line, these effects Have also been addressed in wide population-based studies or in patients with mild cognitive impairment, AD, diabetes or combined pathologies. Most common treatments include glucagon-like peptide 1 receptor agonists; thiazolidinediones; biguanides; sulphonylureas; dipeptidyl peptidase-4 inhibitors, insulin, amylin and others. To assess their impact, we have conducted a systematic search in PubMed to Identify studies addressing the effect of Antidiabetic treatments on AD or AD-like dementia preclinical models And clinical studies, yielding 3560 research items. After screening titles And abstracts, 380 papers met eligibility criteria (original full-text articles, written in English, focused on AD or AD-like dementia, involving antidiabetic treatments, containing data on neuropathological AD markers and/or cognitive function, and conducted in vivo or ex vivo), And 25 additional papers were added through citations, resulting in a Total of 405 primary research articles published between 1996 And 2024. We have reviewed the effects of antidiabetic treatments on tau pathology, neuronal health, oxidative stress and neuroinflammation, vascular alterations, implicated signaling pathways and cognitive function in AD and AD-like dementia preclinical models and patients. Overall, antidiabetic medications represent a promising therapeutic strategy to tackle neurodegeneration and cognitive decline in AD preclinical models. Nevertheless, further research is needed to optimize their clinical effectiveness.
What this study adds
Evidence grade: Low
This is a pooled review of 405 participants. This systematic review gathered 405 studies on how diabetes drugs, such as GLP-1 receptor agonists, thiazolidinediones, biguanides and insulin, affect Alzheimer's-like changes in animal models and in patients. Overall, the medicines looked promising against neurodegeneration and cognitive decline in preclinical models.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Corraliza-Gomez, M., Vargas-Soria, M., & Garcia-Alloza, M. (2025). Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies. Molecular neurodegeneration. https://doi.org/10.1186/s13024-025-00894-1
Vancouver
Corraliza-Gomez M, Vargas-Soria M, Garcia-Alloza M. Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies. Molecular neurodegeneration. 2025. doi:10.1186/s13024-025-00894-1. PMID: 41146261.
BibTeX
@article{corralizagomez2025-41146261,
author = {Corraliza-Gomez, M. and Vargas-Soria, M. and Garcia-Alloza, M.},
title = {{Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies}},
journal = {Molecular neurodegeneration},
year = {2025},
doi = {10.1186/s13024-025-00894-1},
pmid = {41146261},
url = {https://doi.org/10.1186/s13024-025-00894-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Overall, antidiabetic medications represent a promising therapeutic strategy to tackle neurodegeneration and cognitive decline in AD preclinical models.
Why it matters
This systematic review gathered 405 studies on how diabetes drugs, such as GLP-1 receptor agonists, thiazolidinediones, biguanides and insulin, affect Alzheimer's-like changes in animal models and in patients. Overall, the medicines looked promising against neurodegeneration and cognitive decline in preclinical models. The authors note that further research is needed to optimize their clinical effectiveness, so the strongest support so far comes from lab studies.
Study details
- Study designsystematic review
- Participants405
- Evidence strengthLow
How this study scored 56/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for effect reported because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurodegeneration) |
| Journal's citation record | 2 / 4 | Molecular Neurodegeneration: journal h-index 164 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 405 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 2 / 7 | Cited 13 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 2.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 13 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Mónica Garcı́a-Alloza: h-index 43 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Universidad de Cádiz: institution h-index 267 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41146261) |
| Free to read | 2 / 2 | Free to read |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13024-025-00894-1
- PubMed: 41146261
- Original source →
- Free full text: Molecular Neurodegeneration →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 29.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Inflammation and the immune system from nearby years
Also in Inflammation and the immune system
138 studies in the library are filed under Inflammation and the immune system with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Inflammation and the immune system hub.